Blogs

Latest Blogs

Protein Degraders: Small Molecules Taking out the Trash

A single PROTAC molecule has two different binding ligands attached by a linker. One ligand binds to the target protein and the other recruits an…

Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures

We’re in the midst of a paradigm shift in biomarker science. No longer academic luxuries or exploratory afterthoughts, biomarker signatures…

Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective

The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…

Building a bioanalytical workflow for a vaccine study: The key assays and considerations

The COVID-19 pandemic put vaccines under the spotlight again, and from a scientific perspective at least, innovations have abounded.…

Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach

Oligonucleotide therapeutics have revolutionised the field of medicine over the last decade due to their potential for treating a broad…

The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions

CAR T-cell therapy has transformed cancer treatment, offering new hope for patients with aggressive B cell malignancies like acute lymphoblastic…

Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials

Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…

Quick Links

Talk to our Biomarker Experts